A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

British Journal of Cancer

Volumn 93, Issue 8, 2005, Pages 876-883

  O'Donnell, A ^a,b,f   Padhani, A ^c   Hayes, C ^a,b   Kakkar, A J ^d   Leach, M ^b   Trigo, J M ^a,b   Scurr, M ^a,b   Raynaud, F ^a   Phillips, S ^a   Aherne, W ^a   Hardcastle, A ^a   Workman, P ^a   Hannah, A ^e   Judson, I ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e SUGEN INC   (United States)

^f WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Antiangiogenic therapy; Pharmacodynamics; Pharmacokinetics; Phase I clinical trial

Indexed keywords

ANGIOGENESIS INHIBITOR; CHLORPHENIRAMINE; CREMOPHOR; DEXAMETHASONE; RANITIDINE; SEMAXANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; WARFARIN;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ANGIOGENESIS; ANTIEMETIC ACTIVITY; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; BLOOD TOXICITY; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPHONIA; ENDOMETRIUM TUMOR; FATIGUE; FEMALE; FIBRINOLYSIS; HEADACHE; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TACHYPHYLAXIS; THROMBOPHLEBITIS; TIME SERIES ANALYSIS; UTERUS TUMOR; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRROLES;

EID: 27144531036     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602797     Document Type: Article

References (34)

1. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin Jr WG (2002) Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 109(9): 1745-1751
2. Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shet M, Ogilvie B, Madan A, Parkinson A (2000) Biotransformation of the anti-angiogenic compound SU5416. Drug Metab Dispos 28(12): 1505-1512
3. Choyke PL, Dwyer AJ, Knopp MV (2003) Functional tumour imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17: 509-520
4. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S (2005) A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 55(3): 295-300
5. Cropp G, Rosen L, Mulay M, Langecker P, Hannah A (1999) Pharmacokinetics and pharmacodynamics of SU5416 a phase I, dose escalating trial in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 19: 161a
6. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumour types. Cancer Res 59(1): 99-106
7. Fox S, Gasparini G, Harris A (2001) Angiogenesis: pathological, prognostic, and growth factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2(5): 278-289
8. Galbraith SM, Lodge M, Taylor J, Rustin GJS, Bentzen S, Stirling J, Padhani A (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15: 132-145
9. Ha IS, Um EY, Jung HR, Park HW, Cheong HI, Choi Y (2002) Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 39(5): 1001-1010
10. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD (2004) Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcoma. Clin Cancer Res 10(17): 5732-5740
11. Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18(38): 5356-5362
12. Huang LQ, Whitworth JA, Chesterman CN (1995) Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul Fibrin 6(5): 438-445
13. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M (2002) Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signalling. Mol Cancer Therap 1(5): 295-302
14. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
15. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47: 617-623
16. Jennens RR, Rosenthal MA, Lindeman GJ, Michael M (2004) Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol 22(3): 193-196
17. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sata Y (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19(17): 2138-2146
18. Kuenen BC, Rosen L, Smit E, Parson M, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh W, Peters G, Cropp G, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002a) Dose finding and pharmacokinetic study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol 20(6): 1657-1667
19. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsberg VW, Kostense PJ, Pinedo HM, Hoekman K (2002b) Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22(9): 1500-1505
20. Maloney JP, Silliman C, Ambruso D, Wang J, Tuder R, Voelkel N (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol - Heart Circ Physiol 275(3): H1054-H1061
21. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM (2000) The angiogenesis inhibitor SU5416 has long lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6(12): 4828-4858
22. Miles S, Arasteh K, Gill P, Jacobs M, Friedman-Kein A, Cropp G, Hannah A (2000) A multicentre dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 19: 683
23. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A (2002) Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 33(9): 863-870
24. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF (2004) Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10(12, Part 1): 4048-4054
25. Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A (1999) Phase I dose escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 18: 618
26. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM (2001) The anti-angiogenic protein kinase inhibitors SU5416 and SU06668 inhibit the SCF receptor (c-kit) in a human myeloid leukaemia cell line and in acute myeloid leukaemia blasts. Blood 97(5): 1413-1421
27. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wrigth R, Karrison T, Vokes EE (2004) A randomised phase II trial of the antiangiogenic agent SU5416 in hormone refractory prostate cancer. Clin Cancer Res 10(10): 3365-3370
28. Stopeck A, Sheldon M, Vahedian MG, Cropp G, Gosalia R, Hannah A (2002) Results of a phase I dose escalating study of the antiangiogenic agent, SU5416 in patients with advanced malignancies. Clin Cancer Res 8: 2798-2805
29. Thomas A, Morgan B, Drevs J, Jivan A, Buchert M, Horsfield M, Hennig J, Mross K, Henry A, Ball H, Peng B, Fuxius S, Unger C, O'Byrne K, Laurent D, Dugan M, Steward W (2001) Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colo-rectal cancer. Proc Am Soc Clin Oncol 20: 279
30. Thomas A, Morgan B, Decatris A, Henry A, Pfister C, Souppart C, Gano C, Moss D, Laurent D, Dugan M, Steward W (2002) A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK222584 on a twice-daily schedule in patients with advanced cancer. Proceedings of the NCI/AACR/EORTC Conference November 2002, Amsterdam: Molecular Targets and Cancer Therapeutics, Abstract 244
31. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TA (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intra-vital multi-fluorescence video microscopy. Neoplasia 1(1): 31-41
32. Vaskoczy P, Thruner A, Hirth KP, Schilling L, Schmiedek P, Ullrich A, Menger MD (2000) Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo intravital microscopy: clinical applications. Oncologist 5(Suppl 1): 16-19
33. Wynendaele W, Derua R, Hoylearts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom A (1999) Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 10: 965-971
34. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC (2002) SU5416 and SY5614 inhibit kinase activity of wild-type and mutant FLT-3 receptor tyrosine kinase. Blood 100(8): 2941-2949